Peripheral leukocytes with HLA-DR+/CD8- phenotype are associated with prognosis in patients with lung cancer.
Peripheral leukocytes with HLA-DR+/CD8- phenotype are associated with prognosis in patients with lung cancer.
复制标题
具有HLA-DR/CD8-表型的外周白细胞与肺癌患者的预后相关。
作者：
Haruhiko Nakamura;H. Saji;Idiris Aute;N. Kawasaki;M. Hosaka;A. Ogata;T. Saijo;H. Kato
背景
我们之前报道过，肺癌患者最重要的免疫学预后因素是外周血HLA-DR+淋巴细胞的百分比。
患者和方法
我们使用两种双染组合进行双色流式细胞术分析，以确定淋巴细胞表型 HLA-DR/CD4 和 HLA-DR/CD8，并检查了 51 名非小细胞肺癌患者这些亚群的表达与生存之间的相关性。
结果
HLA-DR+、HLA-DR+/CD4+（激活的辅助/诱导 T 细胞）和 HLA-DR+/CD8+（激活的细胞毒性/抑制性 T 细胞）的百分比与存活率无关。然而，当 HLA-DR+/CD8- 百分比低于正常值时，生存率更高 (p = 0.0267)。外周血HLA-DR+/CD8-淋巴细胞百分比高和低的患者的4年生存率分别为26.0%和53.2%。
结论
HLA-DR+/CD8- 淋巴细胞亚群有力地预测了非小细胞肺癌患者的生存情况。
BACKGROUND
We have previously reported that the most significant immunological prognostic factors in patients with lung cancer are the percentages of peripheral HLA-DR+ lymphocytes.
PATIENTS AND METHODS
We performed two-color flow cytometric analyses using two combinations of double-staining to identify lymphocyte phenotypes HLA-DR/CD4 and HLA-DR/CD8, and examined the correlation between the expression of these subsets and survival in 51 patients with non-small cell lung cancer.
RESULTS
The percentages of HLA-DR+, HLA-DR+/CD4+ (activated helper/inducer T cells) and HLA-DR+/CD8+ (activated cytotoxic/suppressor T cells) did not correlate with survival. However, survival was better when the percentage of HLA-DR+/CD8- was below normal (p = 0.0267). The 4-year survival rate in patients with high and low percentages of peripheral HLA-DR+/CD8- lymphocytes was 26.0% and 53.2%, respectively.
CONCLUSION
The subset of HLA-DR+/CD8- lymphocytes powerfully predicts the survival of patients with non-small cell lung cancer.